Loading...
•
Dec 31, 2020
Verrica Q4 2020 Earnings Report
Verrica reported financial results for Q4 2020, with FDA accepting the resubmitted NDA for VP-102 and Torii Pharmaceutical exercising its option to acquire an exclusive license agreement.
Key Takeaways
Verrica Pharmaceuticals reported a net loss of $13.0 million for the fourth quarter of 2020. The company's NDA for VP-102 was accepted for filing by the FDA, and Torii Pharmaceutical exercised its option to acquire an exclusive license for VP-102 in Japan.
FDA accepted the resubmitted NDA for VP-102 with a PDUFA goal date of June 23, 2021.
Torii Pharmaceutical exercised its option to acquire an exclusive license agreement to develop and commercialize VP-102 in Japan.
Phase 2 CARE-1 clinical study of VP-102 in external genital warts (EGW) achieved positive topline results.
Verrica had aggregate cash, cash equivalents, and marketable securities of $65.5 million as of December 31, 2020.
Verrica
Verrica
Forward Guidance
Verrica anticipates its cash, cash equivalents, and marketable securities will be sufficient to support planned operations at least into the first quarter of 2022.